<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177371</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1494T</org_study_id>
    <secondary_id>NCI-2010-01793</secondary_id>
    <nct_id>NCT01177371</nct_id>
  </id_info>
  <brief_title>High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma</brief_title>
  <official_title>High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide,&#xD;
      before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop&#xD;
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem&#xD;
      cells from a donor are infused into the patient they may help the patient's bone marrow make&#xD;
      stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted&#xD;
      cells from a donor can make an immune response against the body's normal cells. Giving&#xD;
      cyclosporine, methylprednisolone, and methotrexate after transplant may stop this from&#xD;
      happening.&#xD;
&#xD;
      PURPOSE: This clinical trial studies high-dose busulfan and high-dose cyclophosphamide&#xD;
      followed by donor bone marrow transplant in treating patients with leukemia, myelodysplastic&#xD;
      syndrome, multiple myeloma, or recurrent Hodgkin or Non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicity and efficacy of the high-dose chemotherapy regimen which employs&#xD;
      busulfan, cyclophosphamide, and allogeneic bone marrow transplantation.&#xD;
&#xD;
      II. To ascertain feasibility (safety) and efficacy of the use of intensive chemotherapy&#xD;
      regimen (busulfan and cyclophosphamide) followed by allogeneic bone marrow transplantation in&#xD;
      patients with leukemia, myelodysplastic syndromes, multiple myeloma, and lymphoma.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and&#xD;
      cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2 .&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day&#xD;
      0.&#xD;
&#xD;
      GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day&#xD;
      -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day&#xD;
      21 and continuing for 12 months with taper at 9 months. Patients also receive&#xD;
      methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at&#xD;
      4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6 .&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1988</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>obtained at least one month apart beginning no earlier than two month after marrow infusion</time_frame>
    <description>no evidence of leukemia as judged by two peripheral blood smears and two bone marrow aspirates and biopsies. Disease-free and overall survival data will be computed from the day of marrow infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTC and engraftment (bone marrow) toxicity criteria</measure>
    <time_frame>twice weekly</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Childhood Acute Erythroleukemia (M6)</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Megakaryocytic Leukemia (M7)</condition>
  <condition>Childhood Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Childhood Acute Monocytic Leukemia (M5b)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Childhood Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>De Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.&#xD;
TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.&#xD;
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
    <other_name>Enduxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>A-MethaPred</other_name>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>MePRDL</other_name>
    <other_name>Solu-Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria&#xD;
&#xD;
          -  Acute non-lymphocytic leukemia (FAB types M1-M7) in first, or second remission, or&#xD;
             early first or second bone or marrow relapse (&gt;31% marrow blasts and no circulating&#xD;
             peripheral blasts)&#xD;
&#xD;
          -  All patients with acute promyelocytic leukemia in first complete remission who have&#xD;
             received retinoic acid and chemotherapy are not eligible&#xD;
&#xD;
          -  Acute lymphocytic leukemia in first or second remission, or early first or second bone&#xD;
             marrow relapse (31% marrow blasts and no circulating peripheral blasts)&#xD;
&#xD;
          -  Pediatric ALL patients in first complete remission are not eligible&#xD;
&#xD;
          -  Chronic myelogenous leukemia in first or second chronic phase, or accelerated phase&#xD;
&#xD;
          -  Myelodysplastic syndrome =&lt; 50 years&#xD;
&#xD;
          -  Lymphoma patients age =&lt; 50 years (non Hodgkins or Hodgkins) in first or second&#xD;
             relapse, or refractory disease, who are ineligible for autologous bone marrow&#xD;
             transplantation because of tumor in the bone marrow&#xD;
&#xD;
          -  Multiple myeloma patients age =&lt; 50 who have relapsed or are refractory to at least 2&#xD;
             chemo-radiation or chemotherapy regimens&#xD;
&#xD;
          -  Patients who have failed a previous allogeneic bone marrow transplant&#xD;
&#xD;
          -  Patients with inborn errors of metabolism&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 70%&#xD;
&#xD;
          -  Patients must be HTLV-III (HIV) anti-body negative&#xD;
&#xD;
          -  Acute and chronic leukemia patients must be age =&lt; 50 years; patients up to age 60&#xD;
             years for any of these diseases who have a syngeneic donor are eligible&#xD;
&#xD;
          -  Patients (or bone marrow donors) who are HTLV-III (HIV) antibody positive are&#xD;
             ineligible for this study&#xD;
&#xD;
          -  Patients must not have active infection&#xD;
&#xD;
          -  Patients must not have cytotoxic chemotherapeutic agents for at least 4 weeks before&#xD;
             the transplant conditioning regimen is to begin&#xD;
&#xD;
          -  It is recommended but not required that acute leukemia patients undergoing&#xD;
             transplantation in first remission must have received at least one course of&#xD;
             consolidation therapy&#xD;
&#xD;
          -  Patients undergoing transplant in early relapse are eligible for transplant in first&#xD;
             and second relapse only&#xD;
&#xD;
          -  Patients must have no history of acute myocardial infarction in the 6 months prior to&#xD;
             transplantation, angina pectoris requiring nitrate therapy, uncontrolled major&#xD;
             ventricular dysrhythmia, uncontrolled hypertension, or uncontrolled congestive heart&#xD;
             failure&#xD;
&#xD;
          -  A gated-pool radionuclide scan fraction must be &gt;= 50%&#xD;
&#xD;
          -  Serum creatinine must be =&lt; 1.8% and a 24 hour creatinine clearance must be &gt;=&#xD;
             60ml/min&#xD;
&#xD;
          -  Serum direct bilirubin &gt;= 1.8mg%, or serum SGOT or SGPT &gt; twice normal will exclude&#xD;
             patients from this study&#xD;
&#xD;
          -  Severe symptomatic CNS disease of any etiology other than CNS leukemia will exclude&#xD;
             patients from study&#xD;
&#xD;
          -  FEV1 and DLco (corrected) must be &gt;= 60% of normal&#xD;
&#xD;
          -  pO2 &gt; 60mmHg&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus or uncompensated major thyroid or adrenal&#xD;
             dysfunction render patients ineligible&#xD;
&#xD;
          -  Written informed consent must be obtained&#xD;
&#xD;
          -  Patients treated previously with radiation therapy in excess of 1000 cGy (rads) to any&#xD;
             thoracic or abdominal port, or in excess of 3000 cGy (rads) to cranial-spinal ports,&#xD;
             who are not eligible for other protocols are eligible for this study&#xD;
&#xD;
          -  DONOR: All genotypically HLA- or D/DR identical siblings are eligible to be bone&#xD;
             marrow donors so long as their general medical condition permits the safe use of&#xD;
             general or spinal anesthesia; selected donors who are not HLA-identical may be&#xD;
             considered for use as long as they are D/DR identical, MLC compatible, and are in good&#xD;
             condition to safely undergo spinal or general anesthesia&#xD;
&#xD;
          -  DONOR: This protocol will allow the use of donors who are unrelated but are HLA-A, b,&#xD;
             C, D/Dr identical and MLC (mixed lymphocyte culture) compatible&#xD;
&#xD;
          -  Patient must have adequate insurance to cover the cost of the transplant and&#xD;
             hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillard Lazarus</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lazarus, Hillard</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

